•
Jun 30, 2024
Bio-Techne Q4 2024 Earnings Report
Bio-Techne's Q4 2024 financial performance reflected solid results amidst stabilizing end-markets.
Key Takeaways
Bio-Techne reported a 2% increase in net sales for the fourth quarter of fiscal year 2024, reaching $306.1 million. GAAP EPS was $0.25, while adjusted EPS was $0.49. The Diagnostics & Genomics segment showed strong growth, with a 15% increase in net sales.
Organic revenue increased by 1% (2% reported) to $306.1 million.
GAAP EPS was $0.25 versus $0.47 one year ago; adjusted EPS was $0.49 compared to $0.55 one year ago.
Diagnostics & Genomics segment achieved 9% organic growth (15% reported).
Adjusted operating margin was 33.5%, representing a 50 basis-point sequential improvement.
Bio-Techne
Bio-Techne
Bio-Techne Revenue by Segment
Forward Guidance
No specific forward guidance was provided in the release.
Revenue & Expenses
Visualization of income flow from segment revenue to net income